Paying users zone. Data is covered by hidden.

  • Get to Pfizer Inc. for $19.99, or

  • get to whole website for at least 3 months from $49.99.

Microsoft Excel LibreOffice Calc

Pfizer Inc. (PFE)

Enterprise Value to EBITDA (EV/EBITDA)

Difficulty: Intermediate

Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)

Pfizer Inc., EBITDA calculation

USD $ in millions

Microsoft Excel LibreOffice Calc
12 months ended Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Net income attributable to Pfizer Inc. hidden hidden hidden hidden hidden
Add: Net income attributable to noncontrolling interest hidden hidden hidden hidden hidden
Less: Discontinued operations, net of tax hidden hidden hidden hidden hidden
Add: Income tax expense hidden hidden hidden hidden hidden
Earnings before tax (EBT) hidden hidden hidden hidden hidden
Add: Interest expense hidden hidden hidden hidden hidden
Earnings before interest and tax (EBIT) hidden hidden hidden hidden hidden
Add: Depreciation and amortization hidden hidden hidden hidden hidden
Earnings before interest, tax, depreciation and amortization (EBITDA) hidden hidden hidden hidden hidden
Item Description The company
EBITDA To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. Pfizer Inc.'s EBITDA declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.

Enterprise Value to EBITDA Ratio, Current

Pfizer Inc., current EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Selected Financial Data (USD $ in millions)
Enterprise value (EV) hidden
Earnings before interest, tax, depreciation and amortization (EBITDA) hidden
Ratio
EV/EBITDA hidden
Benchmarks
EV/EBITDA, Competitors
Abbott Laboratories hidden
AbbVie Inc. hidden
Allergan PLC hidden
Amgen Inc. hidden
Biogen Inc. hidden
Bristol-Myers Squibb Co. hidden
Celgene Corp. hidden
Eli Lilly & Co. hidden
Gilead Sciences Inc. hidden
Johnson & Johnson hidden
Merck & Co. Inc. hidden
Regeneron Pharmaceuticals Inc. hidden
EV/EBITDA, Sector
Pharmaceuticals & Biotechnology hidden
EV/EBITDA, Industry
Health Care hidden

If company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.

Otherwise, if company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.

Enterprise Value to EBITDA Ratio, Historical

Pfizer Inc., historical EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in millions)
Enterprise value (EV)1 hidden hidden hidden hidden hidden
Earnings before interest, tax, depreciation and amortization (EBITDA)2 hidden hidden hidden hidden hidden
Ratio
EV/EBITDA3 hidden hidden hidden hidden hidden
Benchmarks
EV/EBITDA, Competitors
Abbott Laboratories hidden hidden hidden hidden hidden
AbbVie Inc. hidden hidden hidden hidden hidden
Allergan PLC hidden hidden hidden hidden hidden
Amgen Inc. hidden hidden hidden hidden hidden
Biogen Inc. hidden hidden hidden hidden hidden
Bristol-Myers Squibb Co. hidden hidden hidden hidden hidden
Celgene Corp. hidden hidden hidden hidden hidden
Eli Lilly & Co. hidden hidden hidden hidden hidden
Gilead Sciences Inc. hidden hidden hidden hidden hidden
Johnson & Johnson hidden hidden hidden hidden hidden
Merck & Co. Inc. hidden hidden hidden hidden hidden
Regeneron Pharmaceuticals Inc. hidden hidden hidden hidden hidden
EV/EBITDA, Sector
Pharmaceuticals & Biotechnology hidden hidden hidden hidden hidden
EV/EBITDA, Industry
Health Care hidden hidden hidden hidden hidden

1 See Details »

2 See Details »

2017 Calculations

3 EV/EBITDA = EV ÷ EBITDA
= hidden ÷ hidden = hidden

Ratio Description The company
EV/EBITDA EV/EBITDA is a valuation indicator for the overall company rather than common stock. Pfizer Inc.'s EV/EBITDA ratio increased from 2015 to 2016 but then declined significantly from 2016 to 2017.